Global Immunoassay Industry is Expected to be Worth 25.45 Billion USD by 2021

This report report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the immunoassay market along with the estimates and forecasts of the revenue and market share analysis.

Browse 139 market data tables and 44 figures spread through 204 pages and in-depth TOC on “Immunoassay Market”
Early buyers will receive 10% customization on this report.

The global immunoassay market is expected to reach USD 25.45 Billion by 2021 from USD 17.16 Billion in 2016, at a CAGR of 8.2% from 2016 to 2021. The major factors driving the growth of this market are rising incidences of chronic diseases, extensive use of immunoassays in oncology, technological advancements, and cost-effectiveness & rapid analysis of immunoassays.

This report segments the immunoassay market on the basis of product & service, technology, application, end user, and region. Based on product & service, the immunoassay market is segmented into reagents & kits, analyzers, and software & services. The reagents & kits segment is further segmented into ELISA reagents, rapid test reagents, western blot reagents, ELISPOT reagents, RIA reagents, and PCR reagents. The analyzers segment is further categorized into purchase mode and type. By purchase mode, the analyzers segment is segmented into reagent rental purchase and outright purchase and by type, these are divided into open-end systems and closed-ended systems.

In 2016, the reagents & kits segment is expected to dominate the global immunoassay market. Factors driving this segment include rising number of immunoassay tests due to the increase in aging population, rising prevalence of chronic and infectious diseases, and increased variety of reagents and analytical techniques.

Download the PDF Brochure@

Based on technology, the immunoassay market is segmented into ELISA, rapid tests, western blot tests, ELISPOT, RIA, and PCR. ELISA is further segmented into platform and generation. On the basis of platform, the ELISA market is divided into chemiluminescence immunoassays (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassays (CI).

On the basis of generation, the ELISA market is further divided into first generation, second generation, third generation, and fourth generation and above. The ELISA segment is expected to account for the largest share of the market, owing to expanding use of immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring.

On the basis of application, the immunoassay market is segmented into infectious diseases, endocrinology, bone and mineral disorders, oncology, cardiology, hematology and blood screening, autoimmune diseases, toxicology, neonatal screening, and other applications. The infectious diseases segment is expected to account the largest market share in 2016.

On the basis of end user, the immunoassay market is segmented into hospitals, clinical laboratories, blood banks, research & academic laboratories, pharmaceutical companies, CROs, biotechnology companies, and other end users. The hospitals segment is expected to account for the largest share of the global immunoassay market in 2016. Major factors driving the growth of this market are the rising prevalence of chronic diseases and increasing healthcare infrastructure.

Get the Sample Pages@

On the basis of region, the immunoassay market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as technological advancement in the immunoassay products and rising incidence of chronic diseases.

Key players in the immunoassay market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens AG (Germany), Abbott Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), and bioMérieux SA (France).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441

Contact Info:
Name: Mr. Rohan
Email: Send Email
Organization: MarketsandMarkets

Release ID: 253521